Wells Fargo & Company Edesa Biotech, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.63 - $0.99 $5 - $8	-9 Reduced 7.69%	108 $0
Q2 2023 Aug 15, 2023	BUY	$0.77 - $1.16 $5 - $8	7 Added 6.36%	117 $0
Q1 2023 May 12, 2023	BUY	$0.91 - $2.63 $30 - $86	33 Added 42.86%	110 $0
Q4 2022 Feb 13, 2023	BUY	$0.8 - $8.05 $1 - $16	2 Added 2.67%	77 $0
Q3 2022 Nov 14, 2022	BUY	$1.39 - $9.94 $5 - $39	4 Added 5.63%	75 $0
Q2 2022 Aug 12, 2022	BUY	$1.47 - $2.94 $26 - $52	18 Added 33.96%	71 $0
Q1 2022 May 16, 2022	BUY	$2.72 - $5.97 $2 - $5	1 Added 1.92%	53 $0
Q3 2021 Nov 15, 2021	BUY	$4.2 - $11.92 $21 - $59	5 Added 10.64%	52 $0
Q1 2021 May 13, 2021	BUY	$4.3 - $7.48 $98 - $172	23 Added 95.83%	47 $0
Q4 2020 Feb 09, 2021	BUY	$4.25 - $8.14 $25 - $48	6 Added 33.33%	24 $0
Q3 2020 Nov 05, 2020	BUY	$4.65 - $9.45 $13 - $28	3 Added 20.0%	18 $0
Q2 2020 Aug 13, 2020	SELL	$2.0 - $6.62 $4 - $13	-2 Reduced 11.76%	15 $0
Q1 2020 May 14, 2020	BUY	$1.64 - $4.09 $27 - $69	17 New	17 $0

Ticker EDSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,462,300
Market Cap $38.2M
Description
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress s...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.